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The aim of this study was to investigate in what
ways in vivo anti-in¯ammatory treatment affects
cytokine mRNA expression in situ in both erythema
nodosum leprosum and reversal reaction patients.
Serial biopsies were collected from the patients
undergoing leprosy reactions before and during
pentoxifylline (n = 7) or thalidomide (n = 3) treatment
for erythema nodosum leprosum and prednisone
(n= 3) for reversal reaction. Clinical evolution of the
skin lesion was assessed during the study and semi-
quantitative reverse transcription±polymerase chain
reaction was used to investigate cytokine mRNA
expression at the lesion site. Results showed expres-
sion of interferon-g, interleukin-6, interleukin-10,
interleukin-12 p40, and tumor necrosis factor-a in all
patients tested at the onset of reactional episodes,
but interleukin-4 mRNA was rarely detected in the
lesions (n = 4). Follow-up analysis showed that,
irrespective of the drugs used, tumor necrosis
factor-a mRNA was diminished in 10 of the 13
patients tested. A concomitant decrease of mRNA
accumulation was also observed for interferon-g
(nine of 11 patients), interleukin-6 (nine of 11), and
interleukin-12 p40 (six of eight). An inhibitory effect
on interleukin-10 mRNA was likewise seen after
thalidomide and pentoxifylline, but not subsequent
to prednisone treatment. The data also demonstrated
that cytokine mRNA inhibition correlates to the reso-
lution of the in¯ammatory response in situ (n = 10),
whereas the persistence/enhancement of cytokine
message expression after treatment was associated
with worsening of the skin condition, as seen in three
erythema nodosum leprosum patients whose mainten-
ance of local in¯ammation was accompanied by the
appearance/persistence of interleukin-4 gene expres-
sion in situ subsequent to anti-in¯ammatory treat-
ment. In summary, the participation of cytokines in
leprosy in¯ammatory episodes seems to be directly
associated with the patients' clinical evolution follow-
ing therapy for reaction. Key words: interleukin-12/pent-
oxifylline/thalidomide/tumor necrosis factor-a. J Invest
Dermatol 115:935±941, 2000
I
t has long been believed that the clinical forms of leprosy are
related to the patient's immune response (Kaplan and Cohn,
1986). In this sense, it has been assumed that the host's
capacity to mount a cellular immune response with a Th1
pro®le (Yamamura et al, 1991) induces a protective response
against mycobacteria, as seen in the tuberculoid [borderline
tuberculoid/tuberculoid leprosy (BT/TT)] forms, whereas
low(non)-cellular immune response responsiveness has most often
been associated with development of a Th2 pro®le (Yamamura et al,
1991), which correlates to the susceptible lepromatous forms
(borderline leprosy/lepromatous leprosy). Nevertheless, the natural
course of the disease can be interrupted by in¯ammatory episodes:
the so-called type I (reversal reaction, RR) and type II (erythema
nodosum leprosum, ENL) reactions. Several reports have recently
demonstrated that the re-emergence of cellular immune response in
lepromatous patients seems to occur during ENL and RR episodes
(Verhagen et al, 1997; Rea and Sieling, 1998; Trao et al, 1998).
Although the mechanisms involved in the upregulation of cellular
immune response during reaction remain unknown, cytokines are
considered key ligands in the triggering of pathophysiologic
processes during these in¯ammatory episodes (Sarno and Sampaio,
1996). One of the major modi®cations involved in the in¯amma-
tory manifestations of reactions seems to be the local and systemic
augmentation of tumor necrosis factor (TNF) -a synthesis. The
presence of high levels of TNF-a in the sera of ENL patients
(Sarno et al, 1991), the expression of TNF-a mRNA in RR and
ENL blood samples and lesions (Moraes et al, 1999), and the
expression of TNF-a mRNA and protein in the skin and nerves of
RR patients (Khanolkar-Young et al, 1995) all point to a central
role for TNF-a in the pathophysiology of these reactional states. In
addition, our group and colleagues (Sreenivasan et al, 1998; Moraes
et al, 1999) have recently demonstrated that cytokines such as
interferon (IFN) -g and interleukin (IL) ±12 are also expressed in
the blood and lesions of reactional patients, which suggests that
these cytokines may indeed be involved in the events leading up to
the development of the reaction.
Whereas prednisone has been prescribed for RR, thalidomide
(THAL), prednisone, and, more recently, pentoxifylline have been
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used for the treatment of ENL. THAL, a potent anti-in¯ammatory
drug, is, unfortunately, teratogenic, and prone to exhibit such
adverse effects as constipation, somnolence, and peripheral neuro-
pathy. Even so, the use of THAL in the treatment of ENL has been
considered successful (Sheskin, 1980), so much so that, to date, no
adverse effects of this treatment have been reported (Jadhav et al,
1990; Naafs, 1996). And despite the scarcity of documentation so
far available on the THAL mechanism of action, its use for the
treatment of a diverse range of skin disorders, including actinic
prurigo, discoid lupus erythematosus, BehcËet's syndrome, and
others, has been favored (Tseng et al, 1996). The ®rst documented
description of the inhibitory effect of THAL over TNF-a
production (Sampaio et al, 1991) has led to a better understanding
of its effects (Moreira et al, 1993; Sampaio et al, 1993), not only on
ENL but also on several other syndromes. Since that time, THAL
has been seen as an immunomodulator capable of inhibiting
in¯ammation and the Th1-type response in vitro (McHugh et al,
1995; Moller et al, 1997a). In addition, it has been recently
demonstrated that THAL affects keratinocyte motility and
proliferation, thereby pointing to the possible involvement of
THAL in tissue regeneration, at least in those skin disorders referred
to above (Nasca et al, 1999).
Pentoxifylline (PTX) has been found to be a modulator of the
immune response in light of its ability to inhibit IL-2, IL-6, IL-12,
and IFN-g (Thanhauser et al, 1993; Moller et al, 1997b). The drug
is a methylxanthine derivative that inhibits phosphodiesterase
activity and is most frequently used for the treatment of
intermittent claudication. PTX also decreases TNF-a secretion
(Doherty et al, 1991), and its successful use for the treatment of
ENL (Sarno et al, 1995) seems to be related to its inhibitory
bene®cial effects on TNF-a production both in vivo and in vitro
(Sampaio et al, 1998).
Prednisone (PDN), a member of the corticosteroid family, has
been used to treat both reactional states of leprosy and neuritis
(Pearson, 1981). It has been proposed that steroids exert their
effects by way of a variety of mechanisms. Inhibition of the
synthesis of several pro-in¯ammatory genes (IL-2, IL-12, IFN-g,
TNF-a, among others) is achieved by blocking the action of NFkB
and AP-1 transcriptional factors (Schleimer, 1993). Despite their
broad inhibitory effects and anti-in¯ammatory activity, the
prolonged use of steroids has also been associated with a variety
of unwanted side-effects.
Although, in comparison with PTX and PRED, it has been
suggested that THAL is more effective in treating ENL (Moreira
et al, 1998); however, results from randomized double-blind studies
remain unavailable. Moreover, detailed information on the pro®le
of cytokines in the tissue and their evolution during anti-
in¯ammatory treatment is also lacking. In our study, it was of
interest to determine how treatment for reaction impacts cytokine
mRNA expression in situ in both ENL and RR patients as
evaluated using reverse transcription±polymerase chain reaction
(reverse transcription±PCR).
MATERIALS AND METHODS
Patient population Thirteen multibacillary leprosy patients (11 males
and two females), 15±64 y of age (mean 6 SD = 32 6 15), in treatment at
the Leprosy Out-Patient Unit (Oswaldo Cruz Foundation, Rio de Janeiro,
Brazil), who were undergoing an in¯ammatory reactional episode (ENL,
n = 10; RR, n = 3) were included in the study. The patients were
diagnosed according to the Ridley±Jopling criteria (Ridley and Jopling,
1966) and classi®ed as lepromatous leprosy (n = 6), borderline lepromatous
(n = 6) or borderline border-line (n = 1). All patients were lepromin
negative with a mean bacterial index of 3.1 6 2.3, ranging from 1.3 to 5.5+
and have been undergoing treatment with multidrug therapy (MDT)
according to WHO speci®cations, which was continued throughout the
study.
Biopsies from the reactional lesions were taken from all 13 patients and
processed as described below. The ®rst reactional episode was assessed for
all patients except two (patient 4 and 10). Patients with reaction (ENL)
were treated with either PTX (Hoechst do Brasil, SA), 400 mg three times
a day for a minimum 2 mo period, or THAL, 300 mg per d, whereas RR
patients were prescribed PDN (1 mg per kg body weight). Both THAL and
PDN were progressively reduced until total remission of the in¯ammatory
symptoms was con®rmed. The clinical features of the patients undergoing
reaction are detailed in Table I. Six patients developed reaction prior to the
initiation of MDT (patients 1, 6, 7, 8, 9, and 11); and six other patients (2,
4, 5, 10, 12 and 13) presented with reactions during MDT (between 1 and
12 mo of treatment). Only one individual (patient 3) developed ENL after
completion of chemotherapy.
Clinical evaluation of the reactional lesions was recorded with regard to
the quantity (< 5, between 5 and 10, > 10, and nonexistent), location
(widespread/generalized or localized/restricted to a particular site),
associated in¯ammatory characteristics (presence of necrosis, edema, pain,
and/or in®ltrates), and systemic involvement, such as fever, malaise,
swollen nerves (with or without pain), myalgia, lymphadenitis, arthralgia,
and/or edema (Nery et al, 1999). Following initiation of anti-in¯ammatory
therapy, all the above-mentioned data were reviewed during subsequent
Table I. Clinical features of reactional (ENL or RR) patients included in the study
Patient number Sex Diagnosisa BIb Reaction MDTc
(mo)
Anti-in¯ammatory
treatment f
Follow-up
(d)g
1 M BL 3.3+ ENL 0d THAL 7
2 M LL 4+ ENL 1 THAL 3
3 M BL 2.1+ ENL 60e THAL 7
4 M BL 4.6+ ENL 12 PTX 7
5 F LL 5.5+ ENL 1 PTX 7
6 M LL 3.8+ ENL 0d PTX 15
7 M LL 4.6+ ENL 0d PTX 30
8 M BL 2.8+ ENL 0d PTX 7
9 M LL 5.5+ ENL 0d PTX 7
10 M LL 4+ ENL 9 PTX 7
11 M BL 2.5+ RR 0d PDN 15
12 M BB 1.3+ RR 4 PDN 15
13 F BL 1.5+ RR 6 PDN 15
aLeprosy diagnosis established according to Ridley-Jopling classi®cation.
bEvaluation of systemic bacterial load (Bacterial index, BI) at the time of leprosy diagnosis.
cDuration of multidrug therapy (MDT) before development of reaction.
dPatients who developed ENL/RR before initiation of MDT.
ePatients who developed ENL after completion of MDT (surveillance). Number indicates the number of months that went by before reaction developed after
discontinuation of chemotherapy.
fENL patients were treated with either Thalidomide (THAL, patients 1±3) or Pentoxifylline (PTX, patients 4±10). Patients with RR (numbers 11±13) were treated with
Prednisone (PRED).
gNumber indicates the number of days after initiating anti-in¯ammatory treatment the follow-up biopsy was collected from each patient.
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visits of the patients to the clinic, at which time patient improvement in
clinical condition (noted as reduction in the number and extent of
reactional lesions; involution of the in¯ammatory characteristics associated
with the lesion; and/or disappearance of systemic symptoms) was assessed.
Collection of skin biopsies After informed consent, biopsies (6 mm
punch) were obtained from the patients at the onset (day 0) of reactional
episodes (n = 13) and during anti-in¯ammatory treatment (days 3, 7, 15, or
30) of those ENL patients taking either PTX (seven patients) or THAL
(three patients) and of the three RR patients taking PDN (day 15, Table I).
Reactional biopsies were processed for histologic analysis whenever clinical
diagnosis of reaction was con®rmed by an experienced pathologist. For
future reverse transcription±PCR studies, biopsy samples were immediately
frozen and stored in liquid nitrogen until use.
RNA isolation and cDNA synthesis For RNA isolation, frozen
biopsies were recovered, after which dermis and epidermis were separated
and the dermis homogenized in a Politron PT-3000 in 3 ml of Trizol
(Gibco Laboratories, Gaithersburg, MD). Total RNA was extracted from
the samples according to the manufacturer's instructions at which time 1 mg
RNA obtained from the dermis was reverse transcribed into cDNA.
Reverse transcription reaction was performed as previously described
(Sampaio et al, 1998), and samples from the same patient were processed in
parallel. cDNA samples were stored at ±20°C until further use.
PCR conditions Cytokine-speci®c oligonucleotide primer pair
sequences for b-actin, IL-4, IFN-g (Ehlers and Smith, 1991), and IL-6
(Yamamura et al, 1992) were used as published. IL-10, TNF-a (Stratagene
Cloning System, La Jolla, CA), and IL-12 p40 sequences (obtained at the
GENEBANK and synthesized, Macromolecular Resources, Fort Collins,
CO) are detailed elsewhere (Moraes et al, 1999). The primers were RNA-
speci®c in that both the 5¢ sense and 3¢ anti-sense primers spanned the
junctions of two exons, thus precluding ampli®cation of genomic DNA.
PCR reaction in a total volume of 25 ml was performed as previously
described (Sampaio et al, 1998). Samples were ampli®ed in a DNA
thermocycler 480 (Perkin Elmer Cetus, Emeryville, CA) for 35 (b-actin,
IFN-g, IL-6, IL-10, IL-12) or 40 cycles (IL-4) of denaturation at 94°C for
45 s, annealing at 60°C for 45 s, and extension at 72°C for 90 s. PCR
product (5 ml) was subjected to electrophoresis on 1.7% agarose gels and
visualized by ethidium bromide staining together with a 123 bp DNA
ladder as a molecular weight marker (Gibco). Speci®city of the ampli®ed
bands was validated by their predicted size (Moraes et al, 1999).
Hybridization of PCR product and densitometric analysis For
semiquantitative analysis, PCR products were transferred to Hybond-N
nylon membranes (Amersham Corp., Airlington Heights, IL) and
hybridized (Sampaio et al, 1998) with a radioactive oligonucleotide probe
complementary to sequences internal to those recognized by the speci®c
primers. Oligonucleotide probe sequences (b-actin, IFN-g, IL-6, IL-12,
and TNF-a were used as described (Moraes et al, 1999) and for IL-10, it
was 5¢-GCAGAGTGAAGACTTTCT-3¢. Densitometer analysis was
performed by scanning the images from autoradiographs (Video
Documenting System, Amersham Pharmacia); densitometric values were
obtained via ImageMaster software (Amersham Pharmacia). To make sure
that the samples contained identical quantities of cDNA, b-actin was used
in order to normalize the exact levels of input cDNA present among the
different samples tested. The relative amount of PCR product present in an
individual sample was expressed as percentage relative to the most intense
band (between paired biopsies for each patient) assigned the value of 100.
Augmentation and inhibition rates (%) in the expression of cytokine
messages were de®ned as the difference (> 20%) between the intensity of
PCR bands of treatment versus reactional biopsies in the same individual
(negative values were assigned as mean inhibition, whereas positive values
represent enhanced mRNA expression). Values between 0 6 20% were
de®ned as persistent cytokine mRNA expression.
RESULTS
Kinetics of cytokine mRNA expression in reactional
biopsies during anti-in¯ammatory treatment In order to
determine the in vivo modulation of cytokine mRNA expression in
reactional leprosy, biopsies were obtained from ENL and RR
patients at the onset of the reactional episode and during treatment
with either PTX (n = 7), THAL (n = 3), or PDN (n = 3). The
dynamics of cytokine expression in situ changed in these patients
during the course of anti-in¯ammatory treatment. A longitudinal
analysis of gene expression was assessed in each individual patient
by comparing the intensities of the speci®c PCR products in the
respective tissue samples. As shown in Fig 1, partial or total
inhibition of TNF-a (Fig 1A), IL-6 (Fig 1B), IFN-g (Fig 1C), and
IL-12 (Fig 1D) mRNA was observed in the biopsies of reactional
patients after 3 or 7 d of treatment with THAL (ENL, patients 1
and 2), 7 or 15 d of PTX (ENL, patients 4, 6, and 9), and 15 d of
PDN (RR, patient 12).
It has been previously demonstrated that TNF-a and IL-6
mRNA expression was down-modulated in the ENL lesions
during treatment with THAL or PTX (Sampaio et al, 1998). In our
study, a large number of patients were evaluated and a decreased
TNF-a mRNA accumulation was con®rmed for most of the
reactional patients upon completion of treatment (Fig 2A). In all
but three patients (7, 8, and 10), inhibition of the TNF-a message
(range 25±100%) was detected after 3±15 d of THAL or PTX. A
similar rate of inhibition (30±80%) was also observed among the
RR patients treated with PDN (Fig 2A, patients 11±13).
In general, the same inhibitory pro®le (30±100% inhibition) was
noted for the IL-6 message in the lesions (Fig 2B). Patients 6 and
12 showed moderate inhibition for both IL-6 and TNF-a.
Likewise, when complete or very strong inhibition was detected
in TNF-a mRNA, the IL-6 message was also greatly decreased
(patients 1±3, 9, 11, and 13). On the other hand, for patients 7 and
8, who both demonstrated TNF-a augmentation following therapy
with PTX (Fig 2A), an enhanced expression of IL-6 (Fig 2B) and
of the other cytokines was noted as well (Fig 2).
IFN-g mRNA decreased in nine of the 11 patients analyzed
irrespective of the drug prescribed (Fig 2C). In most cases, strong
inhibition (45±100%) was observed; however, patients 5 and 8,
who were taking PTX, demonstrated an augmented and persistent
IFN-g message (72% and 15%, respectively) at the lesion site.
The inhibitory rate in IL-12 mRNA expression was de®ned in
eight patients during anti-in¯ammatory treatment (Fig 2D). THAL
seemed to be very effective in inhibiting the IL-12 message in vivo
in two patients tested (patients 2 and 3). Subsequent to the in vivo
administration of PTX, the presence of IL-12 during the reactional
episode was inhibited in patient 6. As observed above for TNF-a
and IL-6, the expression of IL-12 mRNA was unaltered in patient
8 but enhanced in patient 7 (Fig 2D). Treatment with PDN greatly
reduced IL-12 mRNA in all three RR patients.
The kinetics of IL-10 mRNA expression was dependent on the
anti-in¯ammatory drug used to treat the patients (Fig 3). As shown in
Figure 1. Kinetic analysis of cytokine mRNA expression in leprosy
biopsies by semi-quantitative RT-PCR. Skin biopsies were obtained
from ENL and RR patients at the onset of reaction (lanes 1, 3, and 5) and
during treatment (lanes 2,4, and 6) with THAL (ENL, patients 1 and 2),
PTX (ENL, patients 4, 6, and 9), and PDN (RR, patient 12). Total RNA
obtained from the different samples was reverse transcribed and the cDNA
was normalized to yield equivalent b-actin products. PCR ampli®cation
and hybridization to speci®c internal oligonucleotides was performed and
the relative amounts of TNF-a (A), IL-6 (B), IFN-g (C), and IL-12 (D)
were compared between samples from each individual patient as described.
Partial or total inhibition of cytokine mRNA was detected in vivo following
anti-in¯ammatory treatment for leprosy reaction.
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Fig 3(A), visualization of thePCRreaction andhybridization in three
patients demonstrated a differential pattern in IL-10 expression for
each of the drugs used. Inhibition of IL-10 was detected when patient
2 was treated with THAL, although persistent IL-10 expression was
observed inpatient 8 (treatedwithPTX) andpatient 12 (who received
PDN). A detailed analysis of all individuals showed that THAL
inhibited around 50% of the IL-10 message in patients 1 and 2,
whereas in patient 3, inhibition was complete (Fig 3B). PDN, on the
contrary, seemed to increase IL-10 mRNA in one RR patient,
whereas persistent expression was detected in the other two RR
individuals. The data concerning the effects of PTX on IL-10 varied.
Half of the ENL patients (6 and 9) presented an inhibitory pro®le,
whereas half (7 and 8) showed enhanced or persistent IL-10
expression (Fig 3B). Again, in these individuals, it seemed that IL-
10 followed the pattern of TNF-a expression.
Dynamic of IL-4 mRNA expression in situ A qualitative
analysis of IL-4 mRNA expression was performed in the reactional
and follow-up biopsies in these same patients (n = 13). In all cases,
the read-out in the gel electrophoresis was a plus/minus evaluation
for the presence/absence of the respective band. IL-4 mRNA was
not detected in the lesions of most of the reactional patients (ENL,
n = 7; RR, n = 2, Table II). In patients 3 and 11, IL-4 was present
during ENL and was negative after treatment. For patients 5 and
10, the IL-4 message detected during ENL was still present after
PTX (Table II). Moreover, IL-4 was observed in two patients, but
only after treatment with PTX (patients 7 and 8). As mentioned
above, these were the same two patients who demonstrated
enhancement/persistence of all cytokines tested, which then
seemed to culminate in the appearance of IL-4 mRNA in situ.
Patterns of inhibition or augmentation were generally repeated
by all the cytokines assessed in the reactional patients. For the most
part, inhibition of TNF-a mRNA also paralleled a decrease in
IFN-g, IL-4, IL-6, IL-10, and IL-12 (patients treated with THAL:
n = 3, and PTX: n = 3), and, as such, suggesting an inhibitory
pro®le. The inverse occurred when TNF-a mRNA accumulation
was maintained (PTX patients 7 and 8, Table II), which de®nes an
enhancement pro®le; however, patient 5, who showed inhibition
of TNF-a, presented persistent IFN-g and IL-4 mRNA expression;
and patient 10, in spite of a lower IL-6 expression, had a persistent
TNF-a and IL-4 message during PTX. For these two patients (5
and 10), an enhancement pro®le is suggested. For the PDN-treated
RR patients, all cytokine mRNA (except IL-10) were inhibited,
thus continuing to suggest a pattern of inhibition (Table II).
Clinical evolution of the reactional lesion paralleled cytokine
gene expression in situ In order to correlate the cytokine
®ndings with the patients' skin condition, evaluation of the clinical
improvement of reactional lesions was assessed during anti-
in¯ammatory therapy as to the quantity, location, associated
in¯ammatory characteristics, and systemic involvement of the
lesions. As can be seen in Table III, six ENL (patients 1±3, 6, 8,
Figure 2. Inhibition/augmentation rates of
cytokine mRNA expression in leprosy reac-
tional tissue. Analysis of TNF-a (A), IL-6 (B),
IFN-g (C), and IL-12 (D) mRNA expression in
biopsies of ENL and RR patients during treat-
ment for reaction by semi-quantitative RT-PCR.
Following hybridization to speci®c internal oligo-
nucleotides, X-ray ®lms were analyzed by densito-
metry and the relative amounts of cytokine
mRNA in the tissue were compared between
samples from each patient. Variation rates (%) in
mRNA expression were established following
comparison of the intensity of PCR bands be-
tween treatment versus reactional biopsies in the
same individual. Numbers 1±3, ENL patients who
were treated with THAL; numbers 4±10, ENL
patients treated with PTX; numbers 11±13, RR
patients treated with PDN.
Figure 3. Effect of anti-in¯ammatory treatment on IL-10 mRNA in
leprosy tissue. As in the legend of Figs 1 and 2: (A) PCR ampli®cation
and hybridization is shown for three patients (2, 8, and 12) at the onset of
the reactional episode (lanes 1, 3, and 5) and during treatment with THAL
(7 d, lane 2), PTX (15 d, lane 4), and PDN (15 d, lane 6). (B) Rates of
inhibition or augmentation in mRNA expression (as described in legend of
Fig 2) are shown for all patients tested.
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and 10) and all three RR patients (11±13) presented more than 10
lesions. Three patients (5, 7, and 9) presented a limited number of
lesions (®ve to 10), but this information was not available for
patient 4. Regarding localization, skin lesions were found to be
generalized in 11 of the 13 patients studied and localized in the
other two (patients 5 and 9). Local in¯ammatory characteristics
associated with the lesions were most commonly found to be pain,
edema, in®ltrates, and hyperesthesia (in the case of RR lesions).
Moreover, eight patients reported the presence of systemic
symptoms (Table III). During follow-up, seven of the 10 ENL
patients (70%) and all three RR patients (100%) showed clinical
improvement (reduction in number and extent of lesions and
involution of in¯ammatory features) after 1±2 wk of treatment.
Besides, in¯ammatory conditions associated with the lesions also
regressed during treatment in all but three patients (7, 8, and 10). It
is noteworthy that the systemic symptoms evidenced by all patients
but one (patient 7) at the beginning of treatment subsided
signi®cantly.
A correlation between cytokine expression and local symptoms
was observed. Generally speaking, an inhibitory cytokine pro®le
was associated with clinical improvement of the lesions (Table III).
All three patients treated with THAL, three of the seven patients
who received PTX (patients 3, 6, and 9), and all three RR patients
experienced amelioration of their skin condition following therapy
in parallel with the inhibition of all cytokines tested in situ. On the
other hand, in patients 7 and 8 (Table III), who suffered a
worsening of local symptoms was followed by enhanced cytokine
expression and the appearance of IL-4 mRNA (Table II).
Moreover, patient 10, who also clinically worsened, had a
persistent TNF-a and IL-4 expression, albeit with inhibition of
Table II. Relationship of IL-4 and overall cytokine mRNA expression in the lesions of patients with reaction
IL-4 mRNA expression No. of Status after therapy
cytokines
Patient Reaction Treatment testeda TNFa IFNg IL-6 IL-12 IL-10
1 ± ± 5 ¯b ¯ ¯ ND ¯
2 ± ± 6 ¯ ¯ ¯ ¯ ¯
3 + ± 6 ¯ ¯ ¯ ¯ ¯
4 ± ± 3 ¯ ¯ ND ND ND
5 + + 3 ¯ Ûd ND ND ND
6 ± ± 6 ¯ ¯ ¯ ¯ ¯
7 ± + 6 ­ c ¯ ­ ­ ­
8 ± + 6 ­ ­ ­ Û Û
9 ± ± 4 ¯ ND ¯ ND ¯
10 + + 3 Û ND ¯ ND ND
11 + ± 6 ¯ ¯ ¯ ¯ ­
12 ± ± 6 ¯ ¯ ¯ ¯ Û
13 ± ± 6 ¯ ¯ ¯ ¯ Û
aNumber indicates the amount of cytokines assayed in the RT-PCR for each patient.
bIndicates decreased accumulation of cytokine mRNA in the lesion (decrease in band intensity in the follow-up of more than 20% in comparison to the reactional
sample).
cIndicates increased accumulation of cytokine mRNA in the lesion (increase in band intensity in the follow-up greater than 20% in comparison to the reactional sample).
dIndicates persistent cytokine mRNA expression (variation within 20% in comparison to the reactional sample).
eND, not done.
Table III. Correlation of clinical evolution of reaction and cytokine mRNA expression in situ following anti-in¯ammatory
therapy
Clinical status (onset of reaction)a Follow-up period
Patient No. of lesions Distribution Syst sympt Clinical evolutionb Cytokine pro®lec
1 >10 G Y I Inh
2 >10 G Y I Inh
3 >10 G No I Inh
4 ND G Y I Inh
5 5±10 L Y I Enh (IL-4, IFNg)d
6 >10 G Y I Inh
7 5±10 G Y W Enh
8 >10 G No W Enh
9 5±10 L Y I Inh
10 >10 G Y W Enh (TNFa, IL-4)d
11 >10 G No I Inh (IL-10)d
12 >10 G No I Inh (IL-10)d
13 >10 G No I Inh (IL-10)d
aClinical evaluation of reaction is shown according to the number of lesions, distribution (G, generalized; L, localized), and presence (Yes or No) of systemic symptoms
(Syst Sympt), as described in the Materials and Methods.
bDuring the follow-up period (anti-in¯ammatory therapy), clinical evolution of reaction was recorded as I=Improvement or W=Worsening, as described in Materials and
Methods.
cCytokine pro®le at the lesion site during therapy was de®ned as follows: Inh=Inhibition: when the expression of cytokine mRNAs tested (most or all) decreased during
follow-up. Enh=Enhancement: when the expression of cytokine mRNA (most or all) was persistent or enhanced during the follow-up. In relation to IL-4 expression, the
detection of a positive/positive was referred to as persistent, negative/positive was considered enhancement, and negative/negative as well as positive/negative were de®ned
as decreased.
dCytokines that were persistent or enhanced in situ. IL-4 persistence was considered only when patients maintained PCR positivity during reaction and after anti-
in¯ammatory treatment. ND, not done.
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IL-6 mRNA. Among the 13 patients tested, only one showed a
discrepancy between her skin-related clinical and molecular data.
An improved clinical condition (patient 5) occurred concomitantly
with TNF-a inhibition even though IL-4 and IFN-g expression
persisted and/or increased, which is suggestive of an enhancement
pro®le (Table III).
DISCUSSION
The use of reverse transcription±PCR ampli®cation for the analysis
of cytokine expression at the lesion site and its relationship with
clinical improvement following therapy has been performed in
other skin disorders, as, for example, in psoriasis (Olaniran et al,
1996). In the our study, expression of mRNA at the dermis was
investigated in all leprosy patients via reverse transcription±PCR
both at the onset of the in¯ammatory episode (reaction) and during
the course of anti-in¯ammatory treatment (PTX, THAL, or PDN).
A clear correlation was observed between the cytokine pro®le
found in situ and the pathophysiologic conditions observed during
the progression of leprosy reactions.
It has been shown that treatment with PTX and THAL
decreased local expression of TNF-a and IL-6 mRNA (Sampaio
et al, 1998). The data presented herein con®rmed this observation,
which was also seen to apply to IFN-g and IL-12 in situ as well as to
RR patients treated with PDN. These data support a key role for
cytokines in leprosy in¯ammatory episodes and also corroborate
previous ®ndings (Sreenivasan et al, 1998; Moraes et al, 1999). In
addition, these results seemed to indicate the existence of a direct
correlation between dermatologic improvement and a reduction of
cytokine mRNA, most notably of TNF-a, whereas, on the other
hand, the persistence of in¯ammation seemed to correlate with the
maintenance of high levels of cytokine mRNA expression in tissue.
Phosphodiesterase inhibitors (PTX) and corticosteroids (PDN)
are broad inhibitors of cytokine expression (Rott et al, 1993;
Thanhauser et al, 1993; Rowland et al, 1998); however, it is
believed that THAL has a more speci®c range of action in addition
to demonstrating an inhibitory capacity on IL-6, IL-12, and
TNF-a (Sampaio et al, 1991; McHugh et al, 1995; Moller et al,
1997a). Interestingly, this study showed that treatment with THAL
also affected IFN-g and IL-10 expression in vivo, for which there are
possibly two explanations. One would attest to the direct effect of
the drug itself in that it primarily led to a reduction of mRNA
synthesis/stability of such key cytokines as IL-12 and TNF-a
(Sampaio et al, 1991; Moller et al, 1997a), which, in turn, seemed to
trigger a decrease in the mRNA accumulation of other cytokines.
Another explanation might be that as THAL, PDN, and PTX are
able to downregulate the expression of adhesion molecules (Geitz
et al, 1996; Neuner et al, 1997; Mori et al, 1999), the decreased
accumulation of cytokine mRNA might be associated with the
diminished migration of leukocytes to the lesion site. Both
hypothetical situations might even be occurring simultaneously.
In fact, cytokine inhibition seems to correlate with the resolution of
lesions (Table III) and reduction of cell in®ltrates in the tissue
(Sampaio et al, 1993).
It has been demonstrated in vitro and in vivo that the anti-
in¯ammatory effects of drugs and, in particular, of PTX, could be
mediated through the induction of endogenous anti-in¯ammatory
molecules (Platzer et al, 1995; Jilg et al, 1996; Fujimoto et al, 1999).
The correction of a disturbed cytokine imbalance by way of
induction of IL-10 is the proposed mechanism at work, albeit the
continuing controversy surrounding the available data. The
application of PTX does not affect either the spontaneous or
stimulated production of IL-10 in ex vivo whole blood cultures
from coronary artery bypass grafting patients. Instead, PTX
decreased IL-10 release in lipopolysaccharide-stimulated whole
blood cultures in vitro (Kleinschmidt et al, 1998). Our study showed
that whenever THAL or PTX treatment was introduced,
expression of TNF-a and IL-10 mRNA was diminished in situ
(patients 1±3, 6, and 9), which occurred together with an
amelioration of the patients' clinical condition. Moreover, these
drugs were able to decrease IL-12, IFN-g, and IL-6 mRNA in vivo,
whereas none of these patients later became positive for IL-4. The
data also suggest that the resolution of in¯ammation in these
individuals paralleled the inhibition of Th1 cytokine mRNA
expression without inducing an evident Th2 pro®le in situ. In the
same vein, a previous report (Sampaio et al, 1998) has demonstrated
that orally administered PTX inhibited TNF-a production while
not signi®cantly inducing IL-10 secretion in peripheral blood
mononuclear cell cultures.
In fact, the speci®c in vivo effects of anti-in¯ammatory drugs on
in situ IL-10 mRNA were distinct. On the one hand, THAL and
PTX were able to suppress IL-10 mRNA accumulation. On the
other, PDN showed no inhibition whatsoever, so that a persistent
and/or increased accumulation of IL-10 mRNA was observed in all
three patients. Previous reports have demonstrated that cortico-
steroids exhibit differential effects on Th1 and Th2 cytokines.
Inhibition of IFN-g and enhancement of IL-10 have been reported
in stimulated whole blood cultures treated with low doses of
corticosteroids (Hodge et al, 1999). The same effect was observed
when TNF-a and IL-10 were compared in that IL-10 secretion
was induced in vitro whereas TNF-a was inhibited (Franchimont
et al, 1999). Although the regulatory mechanism of IL-10 mRNA
expression still needs to be determined, in our study, PDN seemed
to be the only drug tested to show a tendency to control
in¯ammation by establishing a Th2 pro®le after in vivo adminis-
tration (Blotta et al, 1997). Even so, IL-4 mRNA was not detected
in any of the patients tested during treatment with PDN (Table II).
An increased accumulation of TNF-a mRNA in two patients
(7 and 8) who received PTX together with enhanced and
persistent IL-10 expression and the appearance of IL-4 mRNA
in vivo was noted. In these patients, the pro®le of cytokines
de®ned herein as enhancement paralleled the maintenance of
such in¯ammatory conditions as active reactional lesions and
histologic features of in¯ammation (Table III). The poor
treatment response on the part of these patients and the
accumulation of TNF-a in situ may have led to the further
induction of such endogenous TNF-a antagonists as IL-4 and
IL-10 (Wang et al, 1994; Suk and Erickson, 1996). In this
context, it is therefore feasible to suggest that IL-4 and IL-10
are able to function as anti-in¯ammatory molecules by blocking
TNF-a production at different levels of cytokine synthesis and
regulation in the persistent reactional lesion (Wang et al, 1995).
The exacerbation of acute in¯ammation provokes the
organism to modulate cytokine production on its own in an
attempt to neutralize this intense and ungovernable type of
response. In this sense, the occurrence of mild reactions could
for the most part be resolved in the absence of anti-
in¯ammatory treatment (JAC Nery, personal communication),
indicating that endogenous antagonists are capable of regulating
in¯ammation. Nonetheless, the use of anti-in¯ammatory drugs is
necessary in most ENL and RR cases to reduce patient
suffering and tissue damage promptly. Therefore, attributing a
dominant inhibitory role to anti-in¯ammatory drugs during the
resolution of in¯ammation seems unwarranted. Our data,
however, support the hypothesis that the introduction of these
drugs has the effect of inducing and/or accelerating the
involution of the in¯ammatory aspects of reaction and that
the combination of endogenous antagonists and anti-in¯amma-
tory drugs is responsible for the regulation of the exacerbated
response in vivo.
In our experience, PTX is a well-tolerated drug generally
associated with the remission of systemic symptoms, lowering of
serum TNF-a levels, and improvement of skin lesions (Sarno and
Sampaio, 1996; Sampaio et al, 1998). The unusual response to PTX
in these patients could also be attributed to: (i) diverse metabolic
pathways that could differentially metabolized the drug; (ii) altered
immunologic responses to the bacteria and the consequently
persistent TNF-a production as uncommon clinical features were
observed in both patients (7 and 8); and/or (iii) activation of
different cell populations involved in the development of reactional
states that might be due to the altered immunologic status.
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